TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Heron Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $10.10 and its highest was $22.40 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $1.22B.
What is Heron Therapeutics’s price target?
The average price target for Heron Therapeutics is $27.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $24.00. The average price target represents 128.79% Increase from the current price of $12.02.
What do analysts say about Heron Therapeutics?
Heron Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is Nov 10, 2021 which is in 2 months.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Aug 09, 2021. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.558 by -$0.062.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 101,910,000 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.558. Following the earnings report the stock price went down -0.339%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Among the largest hedge funds holding Heron Therapeutics’s share is Fisher Asset Management LLC. It holds Heron Therapeutics’s shares valued at 542K.